deferoxamine has been researched along with Pain in 10 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy of a eutectic mixture of local anesthetics (EMLA) in alleviating the pain associated with subcutaneous needle insertion for infusion of the iron-chelating agent, deferoxamine, was examined in 12 patients with homozygous beta-thalassemia." | 5.08 | Use of a eutectic mixture of local anesthetics for prolonged subcutaneous drug administration. ( Berkovitch, M; Davis, S; Donsky, J; Koren, G; Matsui, D; Olivieri, NF, 1995) |
| "The aim of the present study was to investigate the role of the peripheral heme oxygenase (HO)-carbon monoxide (CO) pathway on nociceptive response of rats to the formalin experimental model of pain." | 3.74 | Role of the peripheral heme oxygenase-carbon monoxide pathway on the nociceptive response of rats to the formalin test: evidence for a cGMP signaling pathway. ( Branco, LG; Nascimento, CG, 2007) |
| " Further experience with DFO is needed, both to identify the optimal dosage and to clarify the risks of long-term therapy in patients with renal failure." | 2.37 | Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine. ( Coburn, JW; Norris, KC, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inati, A | 2 |
| Khoriaty, E | 1 |
| Musallam, KM | 1 |
| Taher, AT | 1 |
| Orestes, P | 1 |
| Bojadzic, D | 1 |
| Lee, J | 1 |
| Leach, E | 1 |
| Salajegheh, R | 1 |
| Digruccio, MR | 1 |
| Nelson, MT | 1 |
| Todorovic, SM | 1 |
| Chan, GC | 1 |
| Ng, DM | 1 |
| Fong, DY | 1 |
| Ha, SY | 1 |
| Lau, YL | 1 |
| Nascimento, CG | 1 |
| Branco, LG | 1 |
| Berkovitch, M | 1 |
| Davis, S | 1 |
| Matsui, D | 1 |
| Donsky, J | 1 |
| Koren, G | 1 |
| Olivieri, NF | 1 |
| Lauriola, AL | 1 |
| Tangerini, A | 1 |
| Lodi, A | 1 |
| Gamberini, MR | 1 |
| Testa, MR | 1 |
| Orzincolo, C | 1 |
| De Sanctis, V | 1 |
| Vullo, C | 1 |
| Taher, A | 1 |
| Sheikh-Taha, M | 1 |
| Koussa, S | 1 |
| Neeman, R | 1 |
| Mourad, F | 1 |
| Agarwal, MB | 1 |
| Gupte, SS | 1 |
| Viswanathan, C | 1 |
| Vasandani, D | 1 |
| Ramanathan, J | 1 |
| Desai, N | 1 |
| Puniyani, RR | 1 |
| Chhablani, AT | 1 |
| Canavese, C | 1 |
| Pacitti, A | 1 |
| Segoloni, G | 1 |
| Thea, A | 1 |
| D'Amicone, M | 1 |
| Stratta, P | 1 |
| Rossi, P | 1 |
| Sabbioni, E | 1 |
| Pietra, R | 1 |
| Constantini, S | 1 |
| Coburn, JW | 1 |
| Norris, KC | 1 |
1 review available for deferoxamine and Pain
| Article | Year |
|---|---|
Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine.
Topics: Aluminum; Bone Diseases; Deferoxamine; Hematologic Diseases; Humans; Muscular Diseases; Pain; Risk | 1986 |
4 trials available for deferoxamine and Pain
| Article | Year |
|---|---|
Comparison of subcutaneous infusion needles for transfusion-dependent thalassemia patients by the intrapersonal cross-over assessment model.
Topics: Adolescent; Adult; Chelation Therapy; Child; Cross-Over Studies; Deferoxamine; Edema; Equipment Desi | 2004 |
Use of a eutectic mixture of local anesthetics for prolonged subcutaneous drug administration.
Topics: Anesthetics, Local; beta-Thalassemia; Deferoxamine; Double-Blind Method; Drug Combinations; Female; | 1995 |
Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; De | 2001 |
Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating | 1992 |
5 other studies available for deferoxamine and Pain
| Article | Year |
|---|---|
Iron chelation therapy for patients with sickle cell disease and iron overload.
Topics: Administration, Oral; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Deferip | 2010 |
Free radical signalling underlies inhibition of CaV3.2 T-type calcium channels by nitrous oxide in the pain pathway.
Topics: Adrenochrome; Analgesics, Non-Narcotic; Animals; Calcium Channel Blockers; Calcium Channels, T-Type; | 2011 |
Role of the peripheral heme oxygenase-carbon monoxide pathway on the nociceptive response of rats to the formalin test: evidence for a cGMP signaling pathway.
Topics: Animals; Biliverdine; Carbon Monoxide; Cyclic GMP; Deferoxamine; Deuteroporphyrins; Heme; Heme Oxyge | 2007 |
Rachitic rosary in a well chelated thalassaemic patient with primary amenorrhea (patient report).
Topics: Amenorrhea; beta-Thalassemia; Blood Transfusion; Chelating Agents; Child; Deferoxamine; Female; Huma | 1998 |
Clinical and histological results of long-term management of aluminium overloading in uraemic patients with desferrioxamine.
Topics: Adult; Aluminum; Bone and Bones; Chelation Therapy; Deferoxamine; Electroencephalography; Female; Fo | 1989 |